In multivariate analyses, lower leukocyte count (P = 0.008) and frontline second‐generation TKI therapy size (P < 0.001) were significantly associated with VEMR achievement, but not baseline BCR‐ABL1 level and CML duration. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.